A Multi-center, Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Pharmacodynamics, Efficacy and Safety of 50 mg Tetomilast Administered as Oral Tablets in Patients With Chronic Obstructive Pulmonary Disease Associated With Emphysema THIS STUDY IS CLOSED TO ENROLLMENT AND NEW SITES

Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Pharmacodynamics, Efficacy and Safety of 50 mg Tetomilast Administered as Oral Tablets in Patients With Chronic Obstructive Pulmonary Disease Associated With Emphysema THIS STUDY IS CLOSED TO ENROLLMENT AND NEW SITES

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Tetomilast (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms EMPHASIS
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 07 Aug 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 26 Mar 2015 Planned End Date changed from 1 Nov 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 26 Mar 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top